Harbour BioMed-B announced that the National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for LET003, the company's first next-generation monoclonal antibody targeting ACVR2A/2B developed on the Hu-mAtrIx AI platform, for the treatment of overweight or obesity. LET003 works by dual-target blockade of ACVR2A and ACVR2B. Preclinical studies showed that its pharmacokinetic profile is superior to multiple competing molecules of the same class, and combination therapy with semaglutide can enhance fat loss while preserving lean body mass.
